BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11277315)

  • 1. Insulin release form isolated, human islets after acute or prolonged exposure to glimepiride.
    Del Guerra S; Parentini C; Bracci C; Lupi R; Marselli L; Aragona M; Navalesi R; Marchetti P
    Acta Diabetol; 2000; 37(3):139-41. PubMed ID: 11277315
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations.
    Gregorio F; Ambrosi F; Cristallini S; Filipponi P; Santeusanio F
    Acta Diabetol; 1996 Mar; 33(1):25-9. PubMed ID: 8777281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets.
    Del Guerra S; Marselli L; Lupi R; Boggi U; Mosca F; Benzi L; Del Prato S; Marchetti P
    J Diabetes Complications; 2005; 19(1):60-4. PubMed ID: 15642492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of insulin secretion and its modulation by sulfonylureas.
    Panten U
    Contrib Nephrol; 1989; 73():16-21; discussion 22-3. PubMed ID: 2689091
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.
    Kramer W; Müller G; Geisen K
    Horm Metab Res; 1996 Sep; 28(9):464-8. PubMed ID: 8911984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
    Schwanstecher M; Mnner K; Panten U
    Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview.
    Beck-Nielsen H; Hother-Nielsen O; Pedersen O
    Diabet Med; 1988 Oct; 5(7):613-20. PubMed ID: 2975544
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of a new sulfonylurea on insulin and glucagon secretion in the isolated perfused pancreas].
    Laube H; Fussgänger RD; Schröder KE; Pfeiffer EF
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2186. PubMed ID: 4579624
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):73-9. PubMed ID: 12369729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
    Müller G; Satoh Y; Geisen K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of glycemia level on insulin secretion caused by an hypoglycemic sulfamide (glisoxepide) in dogs].
    Loubatières AL; Ribes G; Loubatières-Mariani MM
    C R Seances Soc Biol Fil; 1972; 166(8):1047-50. PubMed ID: 4573746
    [No Abstract]   [Full Text] [Related]  

  • 14. Uptake of glibornuride by microdissected pancreatic islets.
    Täljedal IB
    Horm Res; 1974; 5(4):211-6. PubMed ID: 4210148
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin stimulus-secretion coupling is triggered by a novel thiazolidinedione/sulfonylurea hybrid in rat pancreatic islets.
    Mendes CP; Postal BG; Oliveira GTC; Castro AJG; Frederico MJS; Moraes ALL; Neuenfeldt PD; Nunes RJ; Menegaz D; Silva FRMB
    J Cell Physiol; 2018 Jan; 234(1):509-520. PubMed ID: 29968920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas.
    Gregorio F; Ambrosi F; Filipponi P; Cristallini S; Santeusanio F
    J Diabetes Complications; 1994; 8(4):204-12. PubMed ID: 7833495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in the activity of the pancreatic islets induced in normal rodents by prolonged treatment with derivatives of sulfonylurea.
    Sodoyez JC; Sodoyez-Goffaux F; Dunbar JC; Foa PP
    Diabetes; 1970 Sep; 19(9):603-9. PubMed ID: 4918835
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A; Ribes G; Mariani MM; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of sulfonylureas on calcium uptake and insulin secretion by islets of Langerhans.
    Malaisse WJ; Mahy M; Malaisse-Lagae F
    Arch Int Pharmacodyn Ther; 1971 Jul; 192(1):205-7. PubMed ID: 4937349
    [No Abstract]   [Full Text] [Related]  

  • 20. Special pharmacology of the new sulfonylurea glimepiride.
    Geisen K
    Arzneimittelforschung; 1988 Aug; 38(8):1120-30. PubMed ID: 2904269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.